Alx Oncology Holdings
$ 1.58
3.95%
12 Jun - close price
- Market Cap 212,609,000 USD
- Current Price $ 1.58
- High / Low $ 1.60 / 1.49
- Stock P/E N/A
- Book Value 1.12
- EPS -1.49
- Next Earning Report 2026-08-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.37 %
- ROE -0.74 %
- 52 Week High 2.66
- 52 Week Low 0.40
About
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. The company is headquartered in Burlingame, California.
Analyst Target Price
$4.60
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-08 | 2026-02-27 | 2025-11-07 | 2025-08-12 | 2025-05-08 | 2025-03-06 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-07 | 2023-11-13 | 2023-08-10 |
| Reported EPS | -0.15 | -0.3697 | -0.41 | -0.44 | -0.4773 | -0.44 | -0.58 | -0.62 | -0.71 | -0.93 | -1.24 | -0.83 |
| Estimated EPS | -0.16 | -0.3525 | -0.37 | -0.31 | -0.309 | -0.39 | -0.66 | -0.7 | -0.71 | -0.84 | -0.89 | -0.86 |
| Surprise | 0.01 | -0.0172 | -0.04 | -0.13 | -0.1683 | -0.05 | 0.08 | 0.08 | 0 | -0.09 | -0.35 | 0.03 |
| Surprise Percentage | 6.25% | -4.8794% | -10.8108% | -41.9355% | -54.466% | -12.8205% | 12.1212% | 11.4286% | 0% | -10.7143% | -39.3258% | 3.4884% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-11 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.16 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ALXO
2026-06-11 20:09:48
ALX Oncology Holdings Inc. stockholders voted on June 10, 2026, to re-elect Class II directors Daniel Curran, Rekha Hemrajani, and Chris Takimoto, to serve until the 2029 annual meeting. Shareholders also approved the compensation of the company's named executive officers on an advisory basis and ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. These decisions were made during the company's Annual Meeting of stockholders, reflecting investor support for the current board, executive pay structure, and auditing firm.
2026-06-10 20:39:31
ALX Oncology Holdings Inc. (ALXO) announced that all voting proposals, including director elections, executive compensation, and auditor ratification, were approved at their 2026 Annual General Meeting. The company also reported progress in its clinical programs, evorpacept and ALX2004, with key data readouts anticipated within the next 12-18 months. This information is based on an AI-generated summary of the AGM audio transcript.
2026-06-04 10:09:30
ALX Oncology Holdings (NASDAQ:ALXO) insiders who bought shares in the past year have seen their investment return positively despite a recent 15% stock dip, with their purchased shares now worth US$279.3k from an initial US$157.8k. While there has been modest insider selling recently, the overall trend over the last year shows more buying than selling, although at prices lower than the current trading price. Insiders currently own 1.2% of the company's stock, valued at US$2.9 million.
2026-06-04 05:09:30
The provided content is empty and does not contain any information about ALX Oncology, its drug programs, or any related readouts. Therefore, a summary cannot be generated.
2026-06-03 22:41:10
ALX Oncology Holdings Inc. (ALXO) is progressing two clinical programs: evorpacept for HER2-positive cancers and ALX2004, an EGFR ADC. Evorpacept has shown strong efficacy, and ALX2004 demonstrates promising safety and dose escalation, with both programs supported by robust funding. Key data and regulatory discussions are anticipated next year, particularly for the ASPEN-09 phase II trial which will refine the CD47 biomarker strategy.
2026-06-02 23:09:39
ALX Oncology Holdings Inc. announced that its leadership will participate in a fireside chat presentation at the 2026 Jefferies Global Healthcare Conference in New York on June 3, 2026, at 5:30 PM ET. A webcast of the presentation will be available on the company's website and archived for 90 days. ALX Oncology is a clinical-stage biotechnology company focused on developing therapies for cancer, with lead candidate evorpacept and a second candidate, ALX2004, in clinical trials.
